I took a look at the Diabetes Care paper from 2015 and the link...

I took a look at the Diabetes Care paper from 2015 and the link to it is below for anyone interested. There is a fair amount of technical information on MPC's given and I reviewed the web site... (message understood). Mesoblast acquired the fucosylation technology from Harvard several months after this publication in order to extend the reach of the MPC's from type 2 to type 1 diabetes. The initial results look good and review of clinical trials dot gov shows they have 3 diabetes trials completed, one was updated as recently as March 2020 suggesting ongoing follow up of patients. Trust use of this technology gives an advantage over cells from other manufacturers. Many different avenues of development with MSC's/MPC's. thanks again

https://care.diabetesjournals.org/content/diacare/38/9/1742.full.pdf